Zoledronic acid-induced acute psychiatric disorder.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 40707825.
- Also identified by DOI 10.1007/s00198-025-07638-3.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
As a bisphosphonate drug, zoledronic acid is widely used in the treatment of osteoporosis, hypercalcemia, Paget's disease, and solid malignant tumors. Common adverse reactions include acute-phase responses such as myalgia, fatigue, arthralgia, and fever, while psychiatric disorders have been infrequently reported. This paper presents a case of acute psychiatric disorder in an osteoporotic patient following intravenous infusion of zoledronic acid for the first time, underscoring the necessity of clinical vigilance regarding such rare adverse reactions during treatment.
Medical subject headings
- Bone Density Conservation Agents
- Diphosphonates
- Imidazoles
- Mental Disorders